Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Abstract: A heavy article inversion device is provided, in which the inverting operations may be performed in a short time by reducing the size of the heavy article inversion device comprising a pair of inversion boards that may be revolved about a common rotary shaft supported in the center of a base between the horizontal state and the angles of revolution of less than 180 degrees from the horizontal state, and a pair of cam plates each fixed to the corresponding one of the pair of inversion boards and having its proximal end side rotatably fixed to the common rotary shaft, in which each one of the pair of cam plates has a curved lower outer circumferential surface extending from the proximal end side toward the radial outside end and which may be engaged by the rod of each respective one of the pair of linear drive mechanisms when the rod is being moved out of and moved back into the corresponding cylinder of the respective liner drive mechanism, thereby causing the respective cam plate to be rotated about the commo

Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1 to R4 independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5 represents H, optionally substituted alkyl, aryl, or aralkyl group, E1 represents O, S, or —NR6, where R6 represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2 represents O, S, or —NR7, where R7 represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1 represents O or S, E2 does not represent O or S, which has an action of suppressing the cytotoxic Ca2+ overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Abstract: A heavy article inversion device is provided, in which the inverting operations may be performed in a short time by reducing the size of the heavy article inversion device comprising a pair of inversion boards that may be revolved about a common rotary shaft supported in the center of a base between the horizontal state and the angles of revolution of less than 180 degrees from the horizontal state, and a pair of cam plates each fixed to the corresponding one of the pair of inversion boards and having its proximal end side rotatably fixed to the common rotary shaft, in which each one of the pair of cam plates has a curved lower outer circumferential surface extending from the proximal end side toward the radial outside end and which may be engaged by the rod of each respective one of the pair of linear drive mechanisms when the rod is being moved out of and moved back into the corresponding cylinder of the respective liner drive mechanism, thereby causing the respective cam plate to be rotated about the commo

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient.

Abstract: A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or —NHCO(CH2)n— where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alkoxy, or an alkyl optionally substituted with a halogen.

Abstract: A spark plug is provided, for a provisional bending process for manufacturing the spark plug, as a work in a condition where an earth electrode is straight and substantially in parallel with an axial line of a center electrode. In the provisional bending process, two searchers individually facing the tip of the center electrode with the tip located therebetween are arranged, positions of the searchers in a first direction perpendicular to the axial line being adjusted for every spark plug. Then a bending punch is driven to press a second end-surface of the other end of the earth electrode down to the searchers so that the earth electrode is provisionally bent at a substantially perpendicular angle to the axial line, the second end-surface being opposite to the first end-surface. Preferably, before the provisional bending process, positioning the work and correcting the position and tilt of the work are performed.

Abstract: A spark plug is provided after a provisional bending process, during which the earth electrode is provisionally bent at almost 90 degrees. The earth electrode, one of both ends is joined to a housing member, has first and second end-side surfaces located mutually back to back and a tip surface connecting both end-side surfaces. A noble metal chip is mounted on the first end-side surface. A bending punch is set, which has a first pressing surface to be fitted to the second end-side surface located and a second pressing surface to be fitted to a tip surface. The bending punch is first moved so that the second pressing surface comes in contact with the tip surface of the earth electrode, and then moved so that the first pressing surface presses the second end-side surface in the axial direction of the center electrode. Accordingly, a main bending process is performed.

Abstract: The present invention is a method and an apparatus for imaging a liquid-filling container in which a light emitting unit is provided for emitting and irradiating light onto the container and a light receiving unit is provided for receiving the light transmitted through the container. The object of the present invention is to provide such a method and an apparatus for imaging a liquid-filling container. This method and apparatus assures reliable detection of the surface of liquid filled in a container or of foreign substance mixed in the liquid or present in the container or the container material not only when the container is transparent, but also when the container is a colored container of a dark color such as black, dark green or dark brown or the container has a frosted surface of when the liquid filled in the container has a dark color.

Abstract: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1 to R4 independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5 represents H, optionally substituted alkyl, aryl, or aralkyl group, E1 represents O, S, or —NR6, where R6 represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2 represents O, S, or —NR7, where R7 represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1 represents O or S, E2 does not represent O or S, which has an action of suppressing the cytotoxic Ca2+ overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Abstract: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.

Abstract: A spark plug is provided after a provisional bending process, during which the earth electrode is provisionally bent at almost 90 degrees. The earth electrode, one of both ends is joined to a housing member, has first and second end-side surfaces located mutually back to back and a tip surface connecting both end-side surfaces. A noble metal chip is mounted on the first end-side surface. A bending punch is set, which has a first pressing surface to be fitted to the second end-side surface located and a second pressing surface to be fitted to a tip surface. The bending punch is first moved so that the second pressing surface comes in contact with the tip surface of the earth electrode, and then moved so that the first pressing surface presses the second end-side surface in the axial direction of the center electrode. Accordingly, a main bending process is performed.

Abstract: A spark plug is provided, for a provisional bending process for manufacturing the spark plug, as a work in a condition where an earth electrode is straight and substantially in parallel with an axial line of a center electrode. In the provisional bending process, two searchers individually facing the tip of the center electrode with the tip located therebetween are arranged, positions of the searchers in a first direction perpendicular to the axial line being adjusted for every spark plug. Then a bending punch is driven to press a second end-surface of the other end of the earth electrode down to the searchers so that the earth electrode is provisionally bent at a substantially perpendicular angle to the axial line, the second end-surface being opposite to the first end-surface. Preferably, before the provisional bending process, positioning the work and correcting the position and tilt of the work are performed.

Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein R1 to R4 independently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, R5 represents H, optionally substituted alkyl, aryl, or aralkyl group, E1 represents O, S, or —NR6, where R6 represents H, an optionally substituted alkyl, aryl, or aralkyl group, E2 represents O, S, or —NR7, where R7 represents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when E1 represents O or S, E2 does not represent O or S, which has an action of suppressing the cytotoxic Ca2+ overload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Abstract: A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): 1

Abstract: The present invention relates to a method and an apparatus for imaging a liquid-filling container in which a plurality of imaging devices each comprising a light emitting unit and a light receiving unit are provided. Light from each light emitting unit is irradiated onto a liquid-filling container and this light transmitted through the container is received by each light receiving unit. The object of the present invention is to provide such method and an apparatus for imaging a liquid-filling container. This method or apparatus allows for simultaneous and highly reliable imaging of two or more kinds of condition of the container. For accomplishing this object, according to the present invention, wavelengths of the lights emitted by the respective light emitting units and received by the respective light receiving units of the imaging devices for imaging the liquid-filling containers are different from each other.

Abstract: A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Ca2+ overload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or —NHCO(CH2)n— where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alkoxy, or an alkyl optionally substituted with a halogen.

Abstract: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Abstract: A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: 1